Epigenetic Variation in the Mu-Opioid Receptor Gene in Infants with Neonatal Abstinence Syndrome
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Objective Neonatal abstinence syndrome (NAS) from in utero opioid exposure is highly variable with genetic factors appearing to play an important role. Epigenetic changes in cytosine:guanine (CpG) dinucleotide methylation can occur after drug exposure and may help to explain NAS variability. We correlated DNA methylation levels in the mu-opioid receptor (OPRM1) promoter in opioid-exposed infants and correlate them with NAS outcomes. Study design DNA samples from cord blood or saliva were analyzed for 86 infants being treated for NAS according to institutional protocol. Methylation levels at 16 OPRM1 CpG sites were determined and correlated with NAS outcome measures, including need for treatment, treatment with >2 medications, and length of hospital stay. We adjusted for co-variates and multiple genetic testing. Results Sixty-five percent of infants required treatment for NAS, and 24% required ≥2 medications. Hypermethylation of the OPRM1 promoter was measured at the −10 CpG in treated versus non-treated infants [adjusted difference δ=3.2% (95% CI 0.3–6.0%), p=0.03; NS after multiple testing correction]. There was hypermethylation at the −14 [δ=4.9% (95% CI 1.8–8.1%), p=0.003], −10 [δ=5.0% (95% CI 2.3–7.7%), p=0.0005)], and +84 [δ=3.5% (95% CI 0.6 – 6.4), p=0.02] CpG sites in infants requiring ≥2 medications which remained significant for −14 and −10 after multiple testing correction. Conclusions Increased methylation within the OPRM1 promoter is associated with worse NAS outcomes, consistent with gene silencing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
The genetics of addictions: uncovering the genes
Goldman, D., Oroszi, G., & Ducci, F. (2005) · Nature Reviews Genetics · doi:10.1038/nrg1635 · Cited by 1,099
Allelic Expression Imbalance of Human mu Opioid Receptor (OPRM1) Caused by Variant A118G
Zhang, Y., Wang, D., Johnson, A. D., Papp, A. C., & Sadée, W. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504942200 · Cited by 563
Pharmacogenetics and Human Molecular Genetics of Opiate and Cocaine Addictions and Their Treatments
Kreek, M. J., Bart, G., Lilly, C., Laforge, K. S., & Nielsen, D. A. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.1.1 · Cited by 391
Self-citationKroslak, T., LaForge, K. S., Gianotti, R. J., Ho, A., Nielsen, D. A., & Kreek, M. J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04738.x · Cited by 213 · cited 1×
“The common 118A>G rs1799971 SNP causes to an amino acid change resulting in a 3-fold increase in the binding affinity of the receptor with b-endorphin, altering the function of the hypothalamic-pituitary-adrenal axis, and vulnerability to addiction.(26,27) Data from animal models and in vivo studies indicate that the…”
BackgroundSelf-citationElevated levels of DNA methylation at the OPRM1 promoter in blood and sperm from male opioid addicts
Chorbov, P., Todorov, P., Lynskey, P., & Cicero, P. (2018) · Journal of Opioid Management · doi:10.5055/jom.2011.0067 · Cited by 135
Epigenetics of drug abuse: predisposition or response
Nielsen, D. A., Utrankar, A., Reyes, J. A., Simons, D. D., & Kosten, T. R. (2012) · Pharmacogenomics · doi:10.2217/pgs.12.94 · Cited by 125 · cited 2×
“Epigenetic changes are important in adults and are triggered by the use of an addictive drug, leading to drug cravings and a diminished response to pharmacotherapy.(13) Cytosine methylation of DNA is a common epigenetic mechanism that occurs through the addition of a methyl group to the cytosine residues of cytosine:g…”
BackgroundSelf-citationArmstrong, D. A., Lesseur, C., Conradt, E., Lester, B. M., & Marsit, C. J. (2014) · The FASEB Journal · doi:10.1096/fj.13-238402 · Cited by 89 · cited 2×
“Cord blood and saliva methylation levels can be considered as biomarkers for OPRM1 methylation in the central nervous system.(35) Although DNA quantity and quality typically are greater from cord blood compared with saliva or buccal cells, it is often difficult to obtain cord blood at the time of delivery from all sub…”
BackgroundSelf-citation
Cited by
Neuroanatomical characteristics of youths with prenatal opioid and poly-drug exposure
Nygaard, E., Slinning, K., Moe, V., Due-Tønnessen, P., Fjell, A., & Walhovd, K. B. (2018) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2018.04.004 · Cited by 58
Convertino, I., Sansone, A. C., Marino, A., Galiulo, M. T., Mantarro, S., Antonioli, L., Fornai, M., Blandizzi, C., & Tuccori, M. (2016) · Drug Safety · doi:10.1007/s40264-016-0435-8 · Cited by 32
Focusing on the Opioid System for Addiction Biomarker Discovery
Belzeaux, R., Lalanne, L., Kieffer, B. L., & Lutz, P.-E. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.12.004 · Cited by 28
Metadata
- Authors
- Wachman, E. M., Hayes, M. J., Lester, B. M., Terrin, N., Brown, M. S., Nielsen, D. A., & Davis, J. M.
- Venue
- The Journal of Pediatrics
- Publisher
- Elsevier BV
- Published
- 2014-09
- Volume
- 165
- Issue
- 3
- Pages
- 472-478
- ISSN
- 0022-3476 (ISSN-L)
- OpenAlex
- W2141632554
- Cited by
- 100
- References
- 8
- FWCI
- 7.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Epigenetic Variation in the Mu-Opioid Receptor Gene in Infants with Neonatal Abstinence Syndrome. https://app.cochat.ai/papers/10.1016/j.jpeds.2014.05.040
- The paper
- Wachman, E. M., Hayes, M. J., Lester, B. M., Terrin, N., Brown, M. S., Nielsen, D. A., & Davis, J. M. (2014). Epigenetic Variation in the Mu-Opioid Receptor Gene in Infants with Neonatal Abstinence Syndrome. The Journal of Pediatrics. https://doi.org/10.1016/j.jpeds.2014.05.040
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.